Evidence of proatherogenic inflammation in polycystic ovary syndrome.
about
Roles of Oxidative Stress in Polycystic Ovary Syndrome and CancersInflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunctionEffect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndromeBeneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome.Identification and treatment of metabolic complications in pediatric obesity.The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS).Evidence of mononuclear cell preactivation in the fasting state in polycystic ovary syndromeA lower-carbohydrate, higher-fat diet reduces abdominal and intermuscular fat and increases insulin sensitivity in adults at risk of type 2 diabetes.Serum Heat Shock Protein 70 Concentration in Relation to Polycystic Ovary Syndrome in a Non-Obese Chinese Population.Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls.Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome.Polycystic ovary syndrome: current status and future perspectiveMindfulness-based stress reduction for overweight/obese women with and without polycystic ovary syndrome: design and methods of a pilot randomized controlled trial.Serum tumor necrosis factor-α, interleukin-6, monocyte chemotactic protein-1 and paraoxonase-1 profiles in women with endometriosis, PCOS, or unexplained infertilityGenetic variation in the Mcp-1 gene promoter associated with the risk of polycystic ovary syndrome.Is PCOS an inflammatory process?The effects of old, new and emerging medicines on metabolic aberrations in PCOS.Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome.Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome.Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell LineRelationship between IL-17 serum level and ambulatory blood pressure in women with polycystic ovary syndrome.Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndromeHepatic steatosis in overweight/obese females: new screening method for those at riskSystematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena.PAI-1 in granulosa cells is suppressed directly by statin and indirectly by suppressing TGF-β and TNF-α in mononuclear cells by insulin-sensitizing drugs.Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome.Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction.Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.Elevated circulating levels of tissue factor in polycystic ovary syndrome.Association study of HNF1A in women with polycystic ovary syndrome.Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.Levels of CD40L and other inflammatory biomarkers in obese and non-obese women with polycystic ovary syndrome.Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).Effect of colchicine on polycystic ovary syndrome: an experimental study.High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome.
P2860
Q26771828-3896428B-348D-4E2C-BB71-6A753EFE21C5Q27011541-B55BC250-13E9-4D04-9901-2EB6CE0675D4Q30384617-E8FA302C-CADA-4C07-81B8-A50F0573CD41Q33559740-86D23DE2-8BE8-4663-8718-E0161A4DE4B5Q33750620-6D579D1B-3AC6-4E9D-999A-1527AA8EF3DFQ33893011-2ABDAE54-5A0A-4716-AE61-058704CD2CEFQ34026512-2771A880-B87D-4DD1-B74F-D32C2EB7A42DQ34396231-38D02C21-C536-4D4E-ADB7-3F009CBD25E0Q34620242-42C29248-E931-494A-96FC-BA9F4163251AQ34684209-3080A207-14ED-464B-BB01-7B21CF3D171AQ34795100-94521377-AB34-45F8-9F5C-E85D01C8F973Q34817037-5F95EF00-F199-4F57-A9BE-8771B9B989BCQ34987386-3CC65F72-7A7F-4EB4-B5EC-A183574B7A43Q35114712-EFFA21D4-9D0B-44C1-A731-9D6F2605030AQ35124537-B9D55D8A-C033-4B4F-B58F-F891015F44ABQ35235594-429C0813-606F-4A07-90C7-6F6EFD8403D7Q35320690-D6A23300-986A-4F2F-B076-5980A4FD8A91Q35527825-81D6D879-5D45-4188-B282-076A29581036Q35633277-0B7FC1D6-AD16-4B4D-840D-BF5FFE547223Q36328060-4D72D52E-2188-499D-A73F-38CE60A9A524Q36369187-D7A7CC7A-59F3-4443-ADAF-745136671F28Q36593085-D51BCCF6-197D-4551-8F18-3C10C573379FQ37057444-79C4C44A-244B-401F-9817-143E099EEA3FQ37410552-E73ACDD1-0A84-40E7-B7F2-FAD7758488D6Q37422832-CAEC2C53-1026-43EE-910B-9986DFACCCD0Q37461182-F276692B-0395-4F96-B6BB-5A86A9DA2556Q37830746-722634CD-0439-4B04-B8CC-B0557E3681B5Q38247074-F3E18D1B-8AE8-4839-9A8C-77FC60B679EEQ38710863-1B047E09-71C7-41D4-86B8-E8CB630C9815Q39202594-FC994CF2-0422-46CB-A37C-C07762554A62Q40867121-79FBE087-3F66-4472-921A-90336485FF85Q42504156-383077EC-AC87-4AEB-AE4F-23FE95CBFE14Q43098000-63962C96-3D17-4A06-BA7B-10728AB27245Q46658751-B4AD75BD-455D-4C25-9B97-D363E81B0410Q47417124-B4E12FA0-D5B6-4CA3-9DE9-0A49488709F4Q51391379-4F220A84-3720-4CBD-BBFD-EB54F26C4BDDQ51544386-418441BB-0FB3-4562-BA02-E59D890E1B15Q52841821-B48E346F-4CCC-4616-AFAA-A67F0AAC472CQ53291647-EC62CECF-E35C-460F-837F-AD97DA57E8F2Q53753200-AAEF6021-F891-412D-B740-EB975F1E6B91
P2860
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@en
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@nl
type
label
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@en
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@nl
prefLabel
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@en
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@nl
P2093
P2860
P1433
P1476
Evidence of proatherogenic inflammation in polycystic ovary syndrome.
@en
P2093
Frank González
John P Kirwan
Judi Minium
Neal S Rote
P2860
P304
P356
10.1016/J.METABOL.2009.02.022
P577
2009-07-01T00:00:00Z